Aliskiren vs enalapril for C3 kidney inflammation
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether aliskiren works better or as well as enalapril to treat C3 glomerulopathy/dense deposit disease confirmed by a kidney biopsy. It may help by improving kidney outcomes in people with this specific kidney condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a child age 6 or older, or an adult
- Your C3 glomerulopathy or dense deposit disease was confirmed by a kidney biopsy within the last 2 years
- At the start, you either are not on kidney-targeting medicines or you are taking one of these: aliskiren, ACE inhibitors, angiotensin receptor blockers, or immune medicines like mycophenolate or steroids
- Your kidney function is high enough: not too low by the trial’s measured clearance level (varies for children vs adults)
- You can safely take the medicines—no known allergy to aliskiren or enalapril/ACE inhibitors
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called OMS906 for people with C3G or ICGN (immune-related kidney diseases). It aims to see if the drug is safe and can reduce kidney damage. You may qualify if you have a confirmed diagnosis, high protein in your urine, and stable kidney function.
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
This trial studies whether iptacopan can improve outcomes and safety for people with C3 glomerulopathy, a kidney disease caused by overactive parts of the immune system. Participants must already be on standard kidney-protecting medicines and meet specific kidney function and urine protein criteria.
This study tests an investigational drug that blocks a protein called ANGPTL3, which may help protect the kidneys in people with type 2 diabetes and diabetic kidney disease. It aims to see if the drug can reduce kidney damage and improve overall health.
This Phase 2 study tests KP104 in people with IgA nephropathy (IgAN) or C3 glomerulopathy (C3G) to see if it improves kidney disease and is safe. It also tracks how the body handles the drug and how it affects disease markers in urine and blood.
This trial studies whether an ACE inhibitor (a blood-pressure/kidney-protecting medicine) is safe and effective for adults with Alport syndrome caused by certain COL4A3/COL4A4/COL4A5 gene variants. It aims to see if treatment can help protect kidney function in people who currently have signs like blood or small amounts of protein in the urine.
Hear when a new C3 Glomerulopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.